A Study to Compare FCD105 Foam to Minocycline 3% Foam, Adapalene 0.3% Foam and Vehicle Foam.

Completed · Phase 2 · Has a placebo group

Conditions studied: Acne Vulgaris

In brief

A study comparing FCD105 to 3% minocycline foam, 0.3% adapalene foam and vehicle foam in patients ≥ 12 years old for the treatment of moderate-to-severe acne.

Key facts

Study ID

NCT04104685

Run by

Vyne Therapeutics Inc.

People needed

446

Starts

2019-09-18

Expected to finish

2020-03-03

Last updated by the study team

2021-02-05

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Has facial acne vulgaris with all of the following:
• 20 to 50 inflammatory lesions (papules and/or pustules) on the face.
• 25 to 100 non-inflammatory lesions (open and closed comedones) on the face.
• IGA score of moderate (3) to severe (4).
• No more than two active nodules on the face.
• Willing to use only the supplied non-medicated cleanser and to refrain from use of any other acne medication, medicated cleanser, excessive sun exposure, and tanning booths for the duration of the study

You may not qualify if…

• Female who is pregnant or lactating, or is planning a pregnancy during the study.
• Acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne), or any dermatological condition of the face that could interfere with the clinical evaluations.
• Facial hair (eg, beard, mustache, etc.) that could interfere with the clinical evaluations.
• Sunburn on the face.
• Severe systemic disease as assessed by the Investigator that might interfere with the conduct of the study or the interpretation of the results.
• Subjects who have a documented history of any of the following:
• Allergy to tetracycline-class antibiotics or to any ingredient in the study drug.
• Pseudomembranous colitis or antibiotic-associated colitis.
• Hepatitis or clinically significant liver damage or clinically significant renal impairment.
• Known or suspected premalignant or malignant disease (excluding successfully treated skin cancers).
• Subjects who have used the following medications:
• Within 1 week prior to randomization:
• Medicated facial cleansers on the face.
• Topical acne treatments on the face (other than those listed below).
• Within 4 weeks prior to randomization:
• Topical retinoids on the face.
• Topical anti-inflammatories and/or corticosteroids on the face.
• Topical corticosteroids on body areas other than the face for more than 15 consecutive days and on more than 10% of the body surface area. In body folds, such as axillary and inguinal regions, only mild topical steroids are allowed for short term use (≤15 consecutive days).
• Systemic antibiotics.
• Systemic acne treatments.
• Within 12 weeks prior to randomization:
• Systemic retinoids.
• Systemic corticosteroids (Note: Intranasal and inhaled corticosteroids may be used throughout the study if the subject is on a stable dose).
• Use of sauna during the 2 weeks prior to randomization.
• Epilation of the face within 2 weeks prior to randomization.

Where it is running

• Foamix Institution #134 — Bryant, Arkansas, United States
• Foamix Institution #121 — Rogers, Arkansas, United States
• Foamix Institution #106 — Encino, California, United States
• Foamix Institution #103 — Fremont, California, United States
• Foamix Institution #122 — Huntington Beach, California, United States
• Foamix Institution #109 — Manhattan Beach, California, United States
• Foamix Institution #132 — San Diego, California, United States
• Foamix Institution #107 — Hialeah, Florida, United States
• Foamix Institution #127 — Lake City, Florida, United States
• Foamix Institution #101 — Miami, Florida, United States
• Foamix Institution #135 — Miami Beach, Florida, United States
• Foamix Institution #118 — Sanford, Florida, United States
• Foamix Institution #120 — Sunrise, Florida, United States
• Foamix Institution #128 — Tampa, Florida, United States
• Foamix Institution #130 — New Albany, Indiana, United States
• Foamix Institution #116 — Plainfield, Indiana, United States
• Foamix Institution #123 — Louisville, Kentucky, United States
• Foamix Institution #126 — Baton Rouge, Louisiana, United States
• Foamix Institution #124 — New Orleans, Louisiana, United States
• Foamix Institution #136 — Watertown, Massachusetts, United States
• Foamix Institution #114 — Clinton Township, Michigan, United States
• Foamix Institution #111 — Fridley, Minnesota, United States
• Foamix Institution #102 — Las Vegas, Nevada, United States
• Foamix Institution #115 — New York, New York, United States
• Foamix Institution #108 — Stony Brook, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.